| Natural History of Hepatitis C
| [0003]
|
| Hepatitis C Virus Infection in the United States
| [0003]
|
| Global Surveillance and Control of Hepatitis C
| [0003]
|
| Genetic Organization and Diversity of the Hepatitis C Virus
| [0004]
|
| Molecular Cloning of the Human Hepatitis C Virus Genome From Japanese Patients with Non-A, Non-B Hepatitis
| [0004]
|
| Structure and Organization of the Hepatitis C Virus Genome Isolated From Human Carriers
| [0004]
|
| Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions
| [0004]
|
| Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Polyprotein Cleavage Sites
| [0004]
|
| Expression and Identification of Hepatitis C Virus Polyprotein Cleavage Products
| [0004]
|
| NS3 is a serine protease required for processing of hepatitis C virus polyprotein
| [0004]
|
| Hepatitis C Virus NS3 Serine Proteinase: Trans-Cleavage Requirements and Processing Kinetics
| [0004]
|
| Evidence that the N-terminal Domain of Nonstructural Protein NS3 From Yellow Fever Virus is a Serine Protease Responsible for Site-Specific Cleavages in the Viral Polyprotein
| [0005]
|
| Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3'-nontranslated region are essential for virus replication in vivo.
| [0005]
|
| Bioorg. Med. Chem. Lett.
| [0006]
|
| Bioorg. Med. Chem. Lett.
| [0006]
|
| Bioorg. Med. Chem. Lett.
| [0006]
|
| Bioorg. Med. Chem. Lett.
| [0006]
|
| Bioorg. Med. Chem. Lett.
| [0006]
|
| Hepatitis C Virus: an Overview of Current Approaches and Progress
| [0007]
|
| Current and Evolving Therapies for Hepatitis C
| [0007]
|
| Suicide Associated with Alfa-Interferon Therapy for Chronic Viral Hepatitis
| [0007]
|
| Side effects of alpha interferon
| [0007]
|
| Interferon Therapy in Chronic Hepatitis C Virus Infection
| [0007]
|
| Application of a New Approach for the Quantitation of Drug Synergism to the Combination of cis-Diamminedichloroplatinum and 1-ß-D-Arabinofuranosylcytosine
| [0027]
|
| Annual Reports in Medicinal Chemistry
| [0030]
|
| Application Of Bioisosterism To New Drug Design
| [0030]
|
| Bioisosteric Replacement And Development Of Lead Compounds In Drug Design
| [0030]
|
| Theoretical Studies Applied To Drug Design:ab initio Electronic Distributions In Bioisosteres
| [0030]
|
| Protective Groups in Organic Chemistry
| [0032]
|
| Protective Groups in Organic Synthesis
| [0048]
[0049]
|
| Nomenclature of α-Amino Acids (Recommendations, 1974
| [0050]
|
| Protective Groups in Organic Chemistry
| [0051]
[0226]
|
| Encyclopedia of Pharmaceutical Technology
| [0100]
|
| J. Org. Chem.
| [0101]
|
| Design of Prodrugs
| [0105]
|
| Methods in Enzymology
| [0105]
|
| Design and Applications of Prodrugs
| [0105]
|
| Advanced Drug Delivery Reviews
| [0105]
|
| J. Pharm. Sci.
| [0105]
|
| Chem. Pharm. Bull.
| [0105]
|
| A.C.S. Symposium Series, and Bioreversible Carriers in Drug Design
| [0105]
|
| Pharmaceutical Salts
| [0106]
|
| Tetrahedron Letter
| [0216]
|
| J. Am. Chem. Soc.
| [0216]
|
| Synlett
| [0217]
|
| J. Org. Chem.
| [0217]
|
| Protective Groups in Organic Synthesis
| [0218]
[0221]
|
| J. Org. Chem.
| [0220]
|
| J. Org. Chem.
| [0220]
|
| J. Org Chem.
| [0221]
|
| The organic Chemistry of β-Lactams
| [0223]
|
| Protective Groups in Organic Chemistry
| [0226]
|
| Tetrahedron
| [0301]
|
| Tetrahedron
| [0311]
|
| J. Med. Chem.
| [0472]
[0474]
|
| Remington's Pharmaceutical Sciences
| [0556]
|
| Biochim. Biophys. Acta
| [0574]
|
| Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C
| [0577]
|
| Efficacy of consensus interferon m the treatment of chronic hepatitis C
| [0577]
|
| IFN-tau, a new interferon type I with antiretroviral activity
| [0577]
|
| Future options for the management of hepatitis C
| [0577]
[0577]
[0577]
[0577]
|
| Russian Experience in Screening, Analysis, and Clinical Application of Novel Interferon Inducers
| [0578]
|
| Immunomodulatory and pharmacologic properties of imiquimod
| [0578]
|
| The roles of amantadine, rimantadine, ursodeoxycholic acid, NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C
| [0579]
|
| Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt
| [0579]
|
| Goodman & Gilman's The Pharmacological Basis of Therapeutics
| [0580]
|
| Goodman & Gilman's The Pharmacological Basis of Therapeutics
| [0580]
|
| Acta Biochim. Pol.
| [0584]
|
| Swed. Nucleosides Nucleotides
| [0584]
|
| Synthesis
| [0584]
|
| Carbohyd. Chem.
| [0584]
|
| Chem. Nucleosides Nucleotides
| [0584]
|
| Ann. Reports in Med. Chem.
| [0584]
|
| Exp. Opin. Invest. Drugs
| [0584]
|
| Hepatology
| [0587]
|
| Chronic Hepatitis C Current Disease Management
| [0592]
|
| Science
| [0593]
[0595]
|
| Cancer Res.
| [0595]
|
| Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line
| [0599]
[0600]
|
| Die Quantitation Probleme der Pharmakologic
| [0620]
|
| The expected effect of a combination of agents: the general solution
| [0622]
|
| Application of a New Approach for the Quantitation of Drug Synergism to the Combination of cis-Diamminedichloroplatinum and 1-β-D-Arabinofuranosylcytosine
| [0622]
|
| Measurement of potencies of drug mixtures
| [0626]
|
| Transformation and Weighting in Regression
| [0627]
|
| Radioligand Assay
| [0627]
|
| Guidelines for Immunoassay Data Processing
| [0627]
|
| Application of a New Approach for the Quantitation of Dmg Synergism to the Combination of cis-Diamminedichloroplatinum and 1-β-D-Arabinofuranosylcytosine
| [0633]
|
| A three-dimensional model to analyze drug-drug interactions (review
| [0633]
|
| Efficient Initiation of HCV RNA Replication in Cell Culture
| [0635]
|
| Hepatitis C virus replication is directly inhibited by IFN-α in a full-length binary expression system
| [0635]
|
| Adverse effects and other safety aspects of the hepatitis C antivirals
| [0635]
|
| Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes
| [0636]
|
| An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT
| [0636]
|
| Comparative quantification of IL-1beta, IL-10, IL-10r, TNFalpha and IL-7 mRNA levels in UV-irradiated human skin in vivo
| [0636]
|
| Chronic Hepatitis C: Current Disease Management
| [0640]
[0640]
|